PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
The patent is for the process of manufacturing antigen-specific T-reg cells, one of several modalities of engineered Treg cells PolTREG is working on. Antigen specific Treg cells have been “trained” to recognize a patient’s biomarkers for a disease – for instance type 1 diabetes – and the expectation is this will make them more targeted … Continued